Regenera receives ethics approval for second clinical trial
Wednesday, 20 October, 2004
Perth's Regenera (ASX: RGA) has received ethics approval for the second of five Phase III clinical trial to be conducted in Singapore using intravitreal injections of its product Visagen to treat macular oedema.
Visagen is a preservative free formulation of the steroid triamcinolone acetonide.
The trials will be conducted in conjunction with the Singapore Eye Research Institute, an arm of the Singapore National Eye Centre.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
